WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406431
CAS#: 496791-37-8
Description: AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10.
MedKoo Cat#: 406431
Name: AR-C155858
CAS#: 496791-37-8
Chemical Formula: C21H27N5O5S
Exact Mass: 461.17329
Molecular Weight: 461.53458
Elemental Analysis: C, 54.65; H, 5.90; N, 15.17; O, 17.33; S, 6.95
ARC-C155858, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: ARC155858; AR-C155858; ARC 155858.
IUPAC/Chemical Name: (S)-6-((3,5-dimethyl-1H-pyrazol-4-yl)methyl)-5-(4-hydroxyisoxazolidine-2-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
InChi Key: ISIVOJWVBJIOFM-ZDUSSCGKSA-N
InChi Code: InChI=1S/C21H27N5O5S/c1-10(2)7-25-20-17(18(28)24(5)21(25)30)16(19(29)26-8-13(27)9-31-26)15(32-20)6-14-11(3)22-23-12(14)4/h10,13,27H,6-9H2,1-5H3,(H,22,23)/t13-/m0/s1
SMILES Code: O=C1N(CC(C)C)C2=C(C(C(N3OC[C@@H](O)C3)=O)=C(CC4=C(C)NN=C4C)S2)C(N1C)=O
The following data is based on the product molecular weight 461.53458 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, Sneddon S, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012 Mar 15;11(6):1108-17. doi: 10.4161/cc.11.6.19530. Epub 2012 Mar 15. PubMed PMID: 22313602; PubMed Central PMCID: PMC3335917.
2: Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouysségur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8. doi: 10.1073/pnas.1106123108. Epub 2011 Sep 19. Erratum in: Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20166. Naïken, Tanesha [corrected to Naiken, Tanesha]; Ilk, Karine [corrected to Ilc, Karine]. PubMed PMID: 21930917; PubMed Central PMCID: PMC3189052.
3: Ovens MJ, Manoharan C, Wilson MC, Murray CM, Halestrap AP. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein. Biochem J. 2010 Oct 15;431(2):217-25. doi: 10.1042/BJ20100890. PubMed PMID: 20695846; PubMed Central PMCID: PMC2947196.
4: Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30. doi: 10.1042/BJ20091515. PubMed PMID: 19929853; PubMed Central PMCID: PMC2811425.